Provided by Tiger Fintech (Singapore) Pte. Ltd.

Iovance Biotherapeutics, Inc.

3.06
-0.0100-0.33%
Post-market: 3.090.0200+0.65%19:24 EDT
Volume:9.65M
Turnover:28.94M
Market Cap:1.00B
PE:-2.38
High:3.09
Open:3.05
Low:2.89
Close:3.07
Loading ...

Iovance Biotherapeutics Is Maintained at Buy by Goldman Sachs

Dow Jones
·
19 hours ago

Is Iovance Biotherapeutics Inc. (NASDAQ:IOVA) the Best Biotech Penny Stock to Buy According to Hedge Funds?

Insider Monkey
·
16 Apr

Barclays Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)

TIPRANKS
·
15 Apr

Iovance Biotherapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
15 Apr

Iovance Biotherapeutics (NasdaqGM:IOVA) Drops 10% Over The Week In Market Correction

Simply Wall St.
·
05 Apr

Traws Pharma Inc - Werner Cautreels to Retire as CEO, Remain as Board Member

THOMSON REUTERS
·
29 Mar

Traws Pharma Inc - Iain Dukes to Become Interim CEO

THOMSON REUTERS
·
29 Mar

Traws Pharma Announces Management Updates

GlobeNewswire
·
29 Mar

Iovance Biotherapeutics (NasdaqGM:IOVA) Stock Dips 27% Despite Reaffirmed 2025 Earnings Guidance

Simply Wall St.
·
05 Mar

Stock Track | Iovance Biotherapeutics Plummets 5.17% as Chardan Cuts Price Target on Mixed Q4 Results

Stock Track
·
04 Mar

Iovance Biotherapeutics price target lowered to $30 from $34 at Chardan

TipRanks
·
04 Mar

Stock Track | Iovance Biotherapeutics Plummets 5.08% After Analysts Cut Price Targets

Stock Track
·
04 Mar

Iovance Biotherapeutics price target lowered to $15 from $25 at Truist

TIPRANKS
·
03 Mar

Stock Track | Iovance Biotherapeutics Soars 5.31% as Analysts Reaffirm "Buy" Ratings

Stock Track
·
03 Mar

Chardan Cuts Price Target on Iovance Biotherapeutics to $30 From $34, Keeps Buy Rating

MT Newswires Live
·
03 Mar

Iovance Biotherapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
03 Mar

Iovance Biotherapeutics (IOVA) Gets a Buy from Truist Financial

TIPRANKS
·
03 Mar

Iovance Biotherapeutics Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
01 Mar

Iovance Shares Fall After Sales of Cancer Drug Miss Estimate

Dow Jones
·
01 Mar

Iovance Biotherapeutics (NasdaqGM:IOVA) Reports Surge in Q4 Revenue to US$74M with Improved Losses

Simply Wall St.
·
01 Mar